Supreme Court Denies Lilly Certiorari Bid In Cialis Patent Row

Mealey's (October 21, 2019, 2:31 PM EDT) -- WASHINGTON, D.C. — In its Oct. 21 orders list, the U.S. Supreme Court announced that it will not review an October 2018 summary affirmance by the Federal Circuit U.S. Court of Appeals that a German company’s prostatic disease treatment patent is valid and infringed by Eli Lilly and Co. (Eli Lilly and Co. v. Erfindergemeinschaft UroPep GbR, No. 18-1515, U.S. Sup.)....